- Home
- TRDA
as 10-17-2024 4:00pm EST
Entrada Therapeutics Inc clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient delivery of a wide range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. Its pipeline includes solutions for Neuromuscular Disease, Beyond Neuromuscular, and Platform Expansion.
| Founded: | 2016 | Country: | United States |
| Employees: | N/A | City: | BOSTON |
| Market Cap: | 609.7M | IPO Year: | 2021 |
| Target Price: | $21.67 | AVG Volume (30 days): | 166.9K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 3.04 | EPS Growth: | N/A |
| 52 Week Low/High: | $10.75 - $18.17 | Next Earning Date: | 11-05-2024 |
| Revenue: | $239,397,000 | Revenue Growth: | 451.22% |
| Revenue Growth (this year): | 39.06% | Revenue Growth (next year): | -71.66% |
Stock Insider Trading Activity of Entrada Therapeutics Inc. (TRDA)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Dowden Nathan J | TRDA | President & COO | Sep 26 '24 | Sell | $16.00 | 847 | $13,552.00 | 125,149 | |
| WENTWORTH KORY JAMES | TRDA | Chief Financial Officer | Sep 9 '24 | Sell | $14.97 | 3,195 | $47,832.35 | 76,486 | |
| Dowden Nathan J | TRDA | President & COO | Sep 6 '24 | Sell | $15.13 | 2,303 | $34,752.92 | 125,149 | |
| Sethuraman Natarajan | TRDA | Chief Scientific Officer | Sep 6 '24 | Sell | $15.16 | 3,242 | $49,003.59 | 186,458 | |
| Dowden Nathan J | TRDA | President & COO | Aug 16 '24 | Sell | $16.48 | 27,097 | $440,801.14 | 125,149 |
Latest Entrada Therapeutics Inc. News
TRDA Breaking Stock News: Dive into TRDA Ticker-Specific Updates for Smart Investing
GlobeNewswire
9 days ago
Entrada Therapeutics Presents New Data Supporting its Expanding Duchenne Franchise at the 29th Annual Congress of the World Muscle Society
GlobeNewswire
24 days ago
Entrada Therapeutics Promotes Natarajan Sethuraman, PhD, to President of Research and Development
GlobeNewswire
a month ago
Entrada Therapeutics Announces Recipients of Second Annual Diversity, Representation, Equity and Advocacy MatterS (DREAMS) Grant Program
Simply Wall St.
2 months ago
Forecast: Analysts Think Entrada Therapeutics, Inc.'s (NASDAQ:TRDA) Business Prospects Have Improved Drastically
Zacks
2 months ago
AstraZeneca (AZN) Imfinzi Combo Gets EU Nod for Uterine Cancer
Zacks
2 months ago
Evotec (EVO) Rises 12% on $75M Milestone Payment From BMY
Zacks
2 months ago
Syros (SYRS) Falls 62% on Phase II Leukemia Study Termination
Zacks
2 months ago
Entrada Therapeutics, Inc. (TRDA) Tops Q2 Earnings and Revenue Estimates
Compare TRDA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "TRDA Entrada Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.